Compare Salesforce Inc (CRM) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Medpace Holdings Inc — how do they compare? Salesforce Inc trades at $228.88 (market cap $187.48B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Salesforce Inc is far larger — about 11.1× Medpace Holdings Inc's market cap, and Salesforce Inc pays a 0.77% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and Medpace Holdings Inc for 14 Days on average.
| CRM | MEDP | |
|---|---|---|
Market Cap | $187.48B | $16.82B |
Volume | 6,155,822 | 223,093 |
Sector | Technology | Health |
52-Week High | $266.23 | $630.19 |
52-Week Low | $150.12 | $393.42 |
Typical Hold Time | 89 Days | 14 Days |
Enterprise Value | $217.82B | $16.44B |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $229.13, up 2.04% today, showing strong fundamental performance with consistent earnings beats and robust revenue growth. The company maintains exceptional profitability with 77.28% gross margins and 21.99% net income margins. Technical indicators show a bearish trend with the stock trading near resistance at $230, while analyst consensus remains strongly bullish with a $271.91 price target representing 19% upside potential.
CRM presents a compelling investment opportunity with strong AI monetization growth and improving profitability, though facing near-term technical headwinds and software sector volatility. The stock trades at reasonable valuations (P/E 20.86) with solid cash flow generation, but investors should monitor competitive pressures and macroeconomic impacts on enterprise software spending.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
